Report overview
This report aims to provide a comprehensive presentation of the global market for CAR-T Therapy in Haematological Malignancy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Therapy in Haematological Malignancy. This report contains market size and forecasts of CAR-T Therapy in Haematological Malignancy in global, including the following market information:
Global CAR-T Therapy in Haematological Malignancy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global CAR-T Therapy in Haematological Malignancy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Allogeneic Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of CAR-T Therapy in Haematological Malignancy include Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics and Mustang Bio, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the CAR-T Therapy in Haematological Malignancy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CAR-T Therapy in Haematological Malignancy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, by Type, 2022 (%)
Allogeneic
Autologous
Global CAR-T Therapy in Haematological Malignancy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, by Application, 2022 (%)
Hospitals
Cancer Research Centers
Others
Global CAR-T Therapy in Haematological Malignancy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CAR-T Therapy in Haematological Malignancy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies CAR-T Therapy in Haematological Malignancy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad
Outline of Major Chapters:
Chapter 1: Introduces the definition of CAR-T Therapy in Haematological Malignancy, market overview.
Chapter 2: Global CAR-T Therapy in Haematological Malignancy market size in revenue.
Chapter 3: Detailed analysis of CAR-T Therapy in Haematological Malignancy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CAR-T Therapy in Haematological Malignancy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
